FR2727015B1 - Compositions pharmaceutiques liquides a base d'ondansetron - Google Patents

Compositions pharmaceutiques liquides a base d'ondansetron

Info

Publication number
FR2727015B1
FR2727015B1 FR9513722A FR9513722A FR2727015B1 FR 2727015 B1 FR2727015 B1 FR 2727015B1 FR 9513722 A FR9513722 A FR 9513722A FR 9513722 A FR9513722 A FR 9513722A FR 2727015 B1 FR2727015 B1 FR 2727015B1
Authority
FR
France
Prior art keywords
pct
ondansetron
pharmaceutical compositions
liquid pharmaceutical
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9513722A
Other languages
English (en)
Other versions
FR2727015A1 (fr
Inventor
Renu Gambhir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Inc
Original Assignee
Glaxo Wellcome Inc Canada
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2727015(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc Canada, Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc Canada
Publication of FR2727015A1 publication Critical patent/FR2727015A1/fr
Application granted granted Critical
Publication of FR2727015B1 publication Critical patent/FR2727015B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FR9513722A 1994-11-22 1995-11-20 Compositions pharmaceutiques liquides a base d'ondansetron Expired - Lifetime FR2727015B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (2)

Publication Number Publication Date
FR2727015A1 FR2727015A1 (fr) 1996-05-24
FR2727015B1 true FR2727015B1 (fr) 1997-08-22

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9513722A Expired - Lifetime FR2727015B1 (fr) 1994-11-22 1995-11-20 Compositions pharmaceutiques liquides a base d'ondansetron

Country Status (33)

Country Link
US (1) US5854270A (fr)
EP (1) EP0792149B1 (fr)
JP (1) JP2965704B2 (fr)
KR (1) KR100292124B1 (fr)
CN (1) CN1108153C (fr)
AT (1) ATE196084T1 (fr)
AU (1) AU703932B2 (fr)
BE (1) BE1009458A5 (fr)
BR (1) BR9509807A (fr)
CA (1) CA2205546C (fr)
CY (1) CY2171B1 (fr)
CZ (1) CZ285187B6 (fr)
DE (1) DE69518767T2 (fr)
DK (1) DK0792149T3 (fr)
ES (1) ES2151083T3 (fr)
FI (1) FI119356B (fr)
FR (1) FR2727015B1 (fr)
GB (2) GB9423588D0 (fr)
GR (1) GR3034684T3 (fr)
HK (1) HK1009590A1 (fr)
HU (1) HU226947B1 (fr)
IE (1) IE950884A1 (fr)
IL (1) IL116083A (fr)
IT (1) IT1282353B1 (fr)
NO (1) NO306892B1 (fr)
NZ (1) NZ297879A (fr)
PL (1) PL181522B1 (fr)
PT (1) PT792149E (fr)
RU (1) RU2145853C1 (fr)
SI (1) SI0792149T1 (fr)
TW (1) TW413634B (fr)
WO (1) WO1996015786A2 (fr)
ZA (1) ZA959820B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
WO2001013909A2 (fr) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions et procedes permettant de traiter l'intolerance aux opiaces
CA2426026A1 (fr) * 2000-10-30 2002-05-10 Judith Aronhime Nouvelles formes de cristaux et solvates de chlorhydrate d'ondansetron et leurs procedes de preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR20040104654A (ko) * 2002-04-29 2004-12-10 비오갈 기오기스제르갸르 알티. 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카르바졸-4-온의 제조 방법
WO2003093260A1 (fr) * 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Nouvelles formes cristallines d'ondansetron, procedes de preparation correspondant, compositions pharmaceutiques contenant ces nouvelles formes et procedes de traitement de la nausee au moyen des ces nouvelles formes
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
WO2004045615A1 (fr) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Methode pour traiter les vomissements
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP3090743A1 (fr) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
US8877768B2 (en) * 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
CA2767576C (fr) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
BR112015004902A2 (pt) 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
WO2017152130A1 (fr) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Compositions pharmaceutiques
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003064B1 (ko) * 1984-01-25 1992-04-13 글락소 그룹 리미티드 헤테로시클릭 화합물의 제조방법
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
ES2151083T3 (es) 2000-12-16
WO1996015786A2 (fr) 1996-05-30
NO972324L (no) 1997-07-21
CA2205546A1 (fr) 1996-05-30
KR100292124B1 (ko) 2001-07-12
GB2295317B (en) 1998-11-25
IE950884A1 (en) 1996-05-29
HK1009590A1 (en) 1999-06-04
HU226947B1 (en) 2010-03-29
GB9423588D0 (en) 1995-01-11
IL116083A0 (en) 1996-01-31
FR2727015A1 (fr) 1996-05-24
DE69518767T2 (de) 2001-05-31
EP0792149A2 (fr) 1997-09-03
GB9523666D0 (en) 1996-01-24
EP0792149B1 (fr) 2000-09-06
GR3034684T3 (en) 2001-01-31
ATE196084T1 (de) 2000-09-15
AU703932B2 (en) 1999-04-01
US5854270A (en) 1998-12-29
IT1282353B1 (it) 1998-03-20
AU4313596A (en) 1996-06-17
IL116083A (en) 2000-09-28
JPH10508866A (ja) 1998-09-02
CN1108153C (zh) 2003-05-14
FI972168A (fi) 1997-05-21
HUT77944A (hu) 1998-12-28
ITRM950763A1 (it) 1997-05-20
CY2171B1 (en) 2002-08-23
SI0792149T1 (en) 2001-02-28
TW413634B (en) 2000-12-01
NZ297879A (en) 1998-12-23
KR970706815A (ko) 1997-12-01
FI972168A0 (fi) 1997-05-21
WO1996015786A3 (fr) 1996-06-27
ITRM950763A0 (fr) 1995-11-20
DK0792149T3 (da) 2000-12-18
BR9509807A (pt) 1997-10-21
JP2965704B2 (ja) 1999-10-18
MX9703734A (es) 1997-09-30
ZA959820B (en) 1996-07-29
PT792149E (pt) 2001-02-28
NO306892B1 (no) 2000-01-10
NO972324D0 (no) 1997-05-21
FI119356B (fi) 2008-10-31
PL181522B1 (en) 2001-08-31
GB2295317A (en) 1996-05-29
DE69518767D1 (de) 2000-10-12
CA2205546C (fr) 2000-01-25
RU2145853C1 (ru) 2000-02-27
PL320288A1 (en) 1997-09-15
CN1171740A (zh) 1998-01-28
BE1009458A5 (fr) 1997-04-01
CZ285187B6 (cs) 1999-06-16
CZ154897A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
FR2727016B1 (fr) Compositions pharmaceutiques a base d'ondansetron
DK0772441T3 (da) Progesteronantagonist og gestagen til behandling af endometriose og leiomyomata

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: GLAXOSMITHKLINE INC., CA

Effective date: 20150109